Although current first-line treatment for DKD is proposed to inhibit the angiotensin-converting enzyme or block the angiotensin II receptor, only an approximate 2-year reprieve from ESRD is gained in type 2 diabetic patients with nephropathy [19, 20]. Here, ACE is linked to diabetic kidney disease.